Revlimid

Fierce Pharma

BMS touts commercial execution, reckons with clinical setbacks

Four failed phase 3 trials of BMS' growth products "collectively have relatively limited impact on the long-term growth of the company," the CEO said.

Angus Liu Jul 31, 2025 11:10am

HaemaLogix's myeloma drug boosts responses in Revlimid combo

Jun 29, 2023 9:10am

Celgene on biotech hunt with Agios, Jounce in crosshairs: FT

Apr 9, 2018 4:08am